2025 Q2 -tulosraportti
190 päivää sittenTarjoustasot
Määrä
Osto
1
Myynti
Määrä
201
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
3,16VWAP
Alin
2,56VaihtoMäärä
3,5 2 113 939
VWAP
Ylin
3,16Alin
2,56VaihtoMäärä
3,5 2 113 939
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 20.3. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 13.8.2025 | ||
2025 Q1 -tulosraportti 14.5.2025 | ||
2024 Q4 -tulosraportti 24.3.2025 | ||
2024 Q3 -tulosraportti 11.11.2024 | ||
2024 Q2 -tulosraportti 14.8.2024 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·14.1.MBRX – Moleculin: 0% cardiotoxicity confirmed + Phase 3 data underway – valuation isn't keeping up! Two press releases from Moleculin Biotech (MBRX) on January 12 & 13 have given us shareholders much to ponder – and even more to hope for. - January 12: The company presents its roadmap for 2026–2028. Focus on Annamycin (AML, STS, pancreatic cancer) and WP1066 (STAT3 inhibitor for brain tumors). The Phase 3 study MIRACLE is now global (9 countries, 46+ sites), and the first unblinding (45 patients) will occur Q1 2026. External studies underway via Atlantic Health, Emory, and Northwestern. - January 13: An independent expert confirms that Annamycin does not cause any cardiotoxicity – not even in patients who received doses far exceeding the FDA's lifetime limit for anthracyclines. 90 patients have now been evaluated, 65 of whom received >550 mg/m², one received >6500(!) mg/m² – without heart damage. What does this mean? - Annamycin could become the first truly non-cardiotoxic anthracycline – a class where heart damage is the biggest limitation. - The safety profile is now validated by an external expert – an important regulatory milestone. - The market potential is enormous: anthracyclines are used in ~50% of all cancer treatments, but are currently limited by cardiac side effects. - The MIRACLE study is well underway – efficacy data from the first 45 patients is expected Q1 2026. - External collaborations (Atlantic Health, Emory, Northwestern) provide validation and reduce capital requirements. Valuation – a ticking bomb? Moleculin is currently valued at approximately 12.5 MUSD. It is a Phase 3 company with a potential blockbuster in oncology – a market where similar companies are often valued at 10–20x more in the equivalent phase. Add to this: • A confirmed safety profile that eliminates one of the biggest regulatory risks. • A pipeline with several candidates (Annamycin, WP1066, WP1122). • A Phase 3 study that will soon be unblinded. • A potential first-in-class product in an area with a billion-dollar market. …and it's hard to understand why the market hasn't already started pricing this in. It smells like strong undervaluation. Risks remain: • Efficacy data is still crucial. Safety is necessary but not sufficient. • Moleculin is a microcap company without revenue – continued development requires capital or a partner. • The market has not yet reacted strongly – the stock even fell slightly on the news. Conclusion: Moleculin has now proven that Annamycin is safe for the heart – something no other anthracycline has achieved. If efficacy data from the MIRACLE study is also positive, this could be a paradigm shift in oncology. WP1066 is also a dark horse with the potential to break through in brain tumors and immunotherapy. It is high risk – but also high potential. 2026 could be the year Moleculin goes from being a speculative microcap to becoming an acquisition candidate or licensing partner for Big Pharma. This could be Moleculin's “make or break” year! MBRX – “Next-gen anthracycline”- ·19.12.2025Moleculin Biotech – Important breakthrough in Phase 1 study of WP1066 for children with brain tumors December 17, 2025 Moleculin (MBRX) has just released a very interesting press release that could be of great importance for the company's future. It concerns positive results from a Phase 1 study of their drug candidate WP1066, targeting recurrent malignant brain tumors in children – one of the most difficult-to-treat cancers with very low survival. What is it about? The study, which was conducted at a leading pediatric cancer center in Atlanta and sponsored by Emory University, tested WP1066 on 10 children with high-grade gliomas (incl. DIPG and DMG). The results show that the drug is well tolerated (no serious side effects) and that it activates the body's immune system against the tumor. One patient with DIPG even showed partial tumor regression – a very unusual finding in this patient group. What does this mean? This is the first time WP1066 has been tested in children, and the results provide clear proof of the mechanism of action. It strengthens Moleculin's scientific credibility and opens the door for a Phase 2 study. It is also an important step towards filling an enormous medical need in pediatric oncology, where the options today are few and insufficient. What does it mean for Moleculin as a company? • The company is now positioning itself as a potential pioneer in immunotherapy for pediatric brain tumors. • Positive data can attract new investors and potential partners. • WP1066's success can validate Moleculin's entire technology platform. . • There is a possibility of licensing agreements or co-development with larger pharmaceutical companies. . • However, continued financing is required to conduct Phase 2 – something the company itself highlights in the press release. Forward-looking If WP1066 continues to show effect in future studies, Moleculin could be facing a breakthrough – both scientifically and commercially. It is still early, but the company now has a concrete foothold in an area with great need and low competition. This could be a game-changer, not just for Moleculin but for the entire field of pediatric cancer treatment. Read more: https://clinicaltrials.gov/ct2/show/NCT04334863 Conclusion – overall impression after the December news This is the fourth press release from Moleculin in a short time (8, 9, 10 and now 17 December), and together they paint a clear picture: the company is in a very active and potentially decisive phase. Earlier in December we have seen: • 8 Dec: Update on the Annamycin program (Phase 3 study in AML) with regulatory progress and continued support from FDA. • 9 Dec: New collaboration around WP1122 for viral indications, which broadens the portfolio beyond oncology. • 10 Dec: Positive preclinical data for WP187 – a new generation of transcription inhibitors with potential in solid tumors. Together, these news show that Moleculin not only has a broad and versatile pipeline, but also that the company is actively driving several projects forward in parallel. This indicates a strong strategic direction and a clear focus on reaching clinical and regulatory milestones. For us investors, this means that Moleculin is now in a position where several triggers can materialize during 2026 – not least if WP1066 proceeds to Phase 2 and the Annamycin program continues as planned. Risks remain high, but the potential is significant.
·17.12.2025How can a stock fall 15% on such news?
·17.12.2025It's very typical of the market... makes no sense
·30.12.2025Yes, that's wild enough, makes no sense at all. I think we'll soon see a nice sqeeze up. Good luck out there and Happy New Year.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q2 -tulosraportti
190 päivää sittenUutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·14.1.MBRX – Moleculin: 0% cardiotoxicity confirmed + Phase 3 data underway – valuation isn't keeping up! Two press releases from Moleculin Biotech (MBRX) on January 12 & 13 have given us shareholders much to ponder – and even more to hope for. - January 12: The company presents its roadmap for 2026–2028. Focus on Annamycin (AML, STS, pancreatic cancer) and WP1066 (STAT3 inhibitor for brain tumors). The Phase 3 study MIRACLE is now global (9 countries, 46+ sites), and the first unblinding (45 patients) will occur Q1 2026. External studies underway via Atlantic Health, Emory, and Northwestern. - January 13: An independent expert confirms that Annamycin does not cause any cardiotoxicity – not even in patients who received doses far exceeding the FDA's lifetime limit for anthracyclines. 90 patients have now been evaluated, 65 of whom received >550 mg/m², one received >6500(!) mg/m² – without heart damage. What does this mean? - Annamycin could become the first truly non-cardiotoxic anthracycline – a class where heart damage is the biggest limitation. - The safety profile is now validated by an external expert – an important regulatory milestone. - The market potential is enormous: anthracyclines are used in ~50% of all cancer treatments, but are currently limited by cardiac side effects. - The MIRACLE study is well underway – efficacy data from the first 45 patients is expected Q1 2026. - External collaborations (Atlantic Health, Emory, Northwestern) provide validation and reduce capital requirements. Valuation – a ticking bomb? Moleculin is currently valued at approximately 12.5 MUSD. It is a Phase 3 company with a potential blockbuster in oncology – a market where similar companies are often valued at 10–20x more in the equivalent phase. Add to this: • A confirmed safety profile that eliminates one of the biggest regulatory risks. • A pipeline with several candidates (Annamycin, WP1066, WP1122). • A Phase 3 study that will soon be unblinded. • A potential first-in-class product in an area with a billion-dollar market. …and it's hard to understand why the market hasn't already started pricing this in. It smells like strong undervaluation. Risks remain: • Efficacy data is still crucial. Safety is necessary but not sufficient. • Moleculin is a microcap company without revenue – continued development requires capital or a partner. • The market has not yet reacted strongly – the stock even fell slightly on the news. Conclusion: Moleculin has now proven that Annamycin is safe for the heart – something no other anthracycline has achieved. If efficacy data from the MIRACLE study is also positive, this could be a paradigm shift in oncology. WP1066 is also a dark horse with the potential to break through in brain tumors and immunotherapy. It is high risk – but also high potential. 2026 could be the year Moleculin goes from being a speculative microcap to becoming an acquisition candidate or licensing partner for Big Pharma. This could be Moleculin's “make or break” year! MBRX – “Next-gen anthracycline”
- ·19.12.2025Moleculin Biotech – Important breakthrough in Phase 1 study of WP1066 for children with brain tumors December 17, 2025 Moleculin (MBRX) has just released a very interesting press release that could be of great importance for the company's future. It concerns positive results from a Phase 1 study of their drug candidate WP1066, targeting recurrent malignant brain tumors in children – one of the most difficult-to-treat cancers with very low survival. What is it about? The study, which was conducted at a leading pediatric cancer center in Atlanta and sponsored by Emory University, tested WP1066 on 10 children with high-grade gliomas (incl. DIPG and DMG). The results show that the drug is well tolerated (no serious side effects) and that it activates the body's immune system against the tumor. One patient with DIPG even showed partial tumor regression – a very unusual finding in this patient group. What does this mean? This is the first time WP1066 has been tested in children, and the results provide clear proof of the mechanism of action. It strengthens Moleculin's scientific credibility and opens the door for a Phase 2 study. It is also an important step towards filling an enormous medical need in pediatric oncology, where the options today are few and insufficient. What does it mean for Moleculin as a company? • The company is now positioning itself as a potential pioneer in immunotherapy for pediatric brain tumors. • Positive data can attract new investors and potential partners. • WP1066's success can validate Moleculin's entire technology platform. . • There is a possibility of licensing agreements or co-development with larger pharmaceutical companies. . • However, continued financing is required to conduct Phase 2 – something the company itself highlights in the press release. Forward-looking If WP1066 continues to show effect in future studies, Moleculin could be facing a breakthrough – both scientifically and commercially. It is still early, but the company now has a concrete foothold in an area with great need and low competition. This could be a game-changer, not just for Moleculin but for the entire field of pediatric cancer treatment. Read more: https://clinicaltrials.gov/ct2/show/NCT04334863 Conclusion – overall impression after the December news This is the fourth press release from Moleculin in a short time (8, 9, 10 and now 17 December), and together they paint a clear picture: the company is in a very active and potentially decisive phase. Earlier in December we have seen: • 8 Dec: Update on the Annamycin program (Phase 3 study in AML) with regulatory progress and continued support from FDA. • 9 Dec: New collaboration around WP1122 for viral indications, which broadens the portfolio beyond oncology. • 10 Dec: Positive preclinical data for WP187 – a new generation of transcription inhibitors with potential in solid tumors. Together, these news show that Moleculin not only has a broad and versatile pipeline, but also that the company is actively driving several projects forward in parallel. This indicates a strong strategic direction and a clear focus on reaching clinical and regulatory milestones. For us investors, this means that Moleculin is now in a position where several triggers can materialize during 2026 – not least if WP1066 proceeds to Phase 2 and the Annamycin program continues as planned. Risks remain high, but the potential is significant.
- ·17.12.2025How can a stock fall 15% on such news?·17.12.2025It's very typical of the market... makes no sense·30.12.2025Yes, that's wild enough, makes no sense at all. I think we'll soon see a nice sqeeze up. Good luck out there and Happy New Year.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
1
Myynti
Määrä
201
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
3,16VWAP
Alin
2,56VaihtoMäärä
3,5 2 113 939
VWAP
Ylin
3,16Alin
2,56VaihtoMäärä
3,5 2 113 939
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 20.3. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 13.8.2025 | ||
2025 Q1 -tulosraportti 14.5.2025 | ||
2024 Q4 -tulosraportti 24.3.2025 | ||
2024 Q3 -tulosraportti 11.11.2024 | ||
2024 Q2 -tulosraportti 14.8.2024 |
2025 Q2 -tulosraportti
190 päivää sittenUutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 20.3. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 13.8.2025 | ||
2025 Q1 -tulosraportti 14.5.2025 | ||
2024 Q4 -tulosraportti 24.3.2025 | ||
2024 Q3 -tulosraportti 11.11.2024 | ||
2024 Q2 -tulosraportti 14.8.2024 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·14.1.MBRX – Moleculin: 0% cardiotoxicity confirmed + Phase 3 data underway – valuation isn't keeping up! Two press releases from Moleculin Biotech (MBRX) on January 12 & 13 have given us shareholders much to ponder – and even more to hope for. - January 12: The company presents its roadmap for 2026–2028. Focus on Annamycin (AML, STS, pancreatic cancer) and WP1066 (STAT3 inhibitor for brain tumors). The Phase 3 study MIRACLE is now global (9 countries, 46+ sites), and the first unblinding (45 patients) will occur Q1 2026. External studies underway via Atlantic Health, Emory, and Northwestern. - January 13: An independent expert confirms that Annamycin does not cause any cardiotoxicity – not even in patients who received doses far exceeding the FDA's lifetime limit for anthracyclines. 90 patients have now been evaluated, 65 of whom received >550 mg/m², one received >6500(!) mg/m² – without heart damage. What does this mean? - Annamycin could become the first truly non-cardiotoxic anthracycline – a class where heart damage is the biggest limitation. - The safety profile is now validated by an external expert – an important regulatory milestone. - The market potential is enormous: anthracyclines are used in ~50% of all cancer treatments, but are currently limited by cardiac side effects. - The MIRACLE study is well underway – efficacy data from the first 45 patients is expected Q1 2026. - External collaborations (Atlantic Health, Emory, Northwestern) provide validation and reduce capital requirements. Valuation – a ticking bomb? Moleculin is currently valued at approximately 12.5 MUSD. It is a Phase 3 company with a potential blockbuster in oncology – a market where similar companies are often valued at 10–20x more in the equivalent phase. Add to this: • A confirmed safety profile that eliminates one of the biggest regulatory risks. • A pipeline with several candidates (Annamycin, WP1066, WP1122). • A Phase 3 study that will soon be unblinded. • A potential first-in-class product in an area with a billion-dollar market. …and it's hard to understand why the market hasn't already started pricing this in. It smells like strong undervaluation. Risks remain: • Efficacy data is still crucial. Safety is necessary but not sufficient. • Moleculin is a microcap company without revenue – continued development requires capital or a partner. • The market has not yet reacted strongly – the stock even fell slightly on the news. Conclusion: Moleculin has now proven that Annamycin is safe for the heart – something no other anthracycline has achieved. If efficacy data from the MIRACLE study is also positive, this could be a paradigm shift in oncology. WP1066 is also a dark horse with the potential to break through in brain tumors and immunotherapy. It is high risk – but also high potential. 2026 could be the year Moleculin goes from being a speculative microcap to becoming an acquisition candidate or licensing partner for Big Pharma. This could be Moleculin's “make or break” year! MBRX – “Next-gen anthracycline”
- ·19.12.2025Moleculin Biotech – Important breakthrough in Phase 1 study of WP1066 for children with brain tumors December 17, 2025 Moleculin (MBRX) has just released a very interesting press release that could be of great importance for the company's future. It concerns positive results from a Phase 1 study of their drug candidate WP1066, targeting recurrent malignant brain tumors in children – one of the most difficult-to-treat cancers with very low survival. What is it about? The study, which was conducted at a leading pediatric cancer center in Atlanta and sponsored by Emory University, tested WP1066 on 10 children with high-grade gliomas (incl. DIPG and DMG). The results show that the drug is well tolerated (no serious side effects) and that it activates the body's immune system against the tumor. One patient with DIPG even showed partial tumor regression – a very unusual finding in this patient group. What does this mean? This is the first time WP1066 has been tested in children, and the results provide clear proof of the mechanism of action. It strengthens Moleculin's scientific credibility and opens the door for a Phase 2 study. It is also an important step towards filling an enormous medical need in pediatric oncology, where the options today are few and insufficient. What does it mean for Moleculin as a company? • The company is now positioning itself as a potential pioneer in immunotherapy for pediatric brain tumors. • Positive data can attract new investors and potential partners. • WP1066's success can validate Moleculin's entire technology platform. . • There is a possibility of licensing agreements or co-development with larger pharmaceutical companies. . • However, continued financing is required to conduct Phase 2 – something the company itself highlights in the press release. Forward-looking If WP1066 continues to show effect in future studies, Moleculin could be facing a breakthrough – both scientifically and commercially. It is still early, but the company now has a concrete foothold in an area with great need and low competition. This could be a game-changer, not just for Moleculin but for the entire field of pediatric cancer treatment. Read more: https://clinicaltrials.gov/ct2/show/NCT04334863 Conclusion – overall impression after the December news This is the fourth press release from Moleculin in a short time (8, 9, 10 and now 17 December), and together they paint a clear picture: the company is in a very active and potentially decisive phase. Earlier in December we have seen: • 8 Dec: Update on the Annamycin program (Phase 3 study in AML) with regulatory progress and continued support from FDA. • 9 Dec: New collaboration around WP1122 for viral indications, which broadens the portfolio beyond oncology. • 10 Dec: Positive preclinical data for WP187 – a new generation of transcription inhibitors with potential in solid tumors. Together, these news show that Moleculin not only has a broad and versatile pipeline, but also that the company is actively driving several projects forward in parallel. This indicates a strong strategic direction and a clear focus on reaching clinical and regulatory milestones. For us investors, this means that Moleculin is now in a position where several triggers can materialize during 2026 – not least if WP1066 proceeds to Phase 2 and the Annamycin program continues as planned. Risks remain high, but the potential is significant.
- ·17.12.2025How can a stock fall 15% on such news?·17.12.2025It's very typical of the market... makes no sense·30.12.2025Yes, that's wild enough, makes no sense at all. I think we'll soon see a nice sqeeze up. Good luck out there and Happy New Year.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
1
Myynti
Määrä
201
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
3,16VWAP
Alin
2,56VaihtoMäärä
3,5 2 113 939
VWAP
Ylin
3,16Alin
2,56VaihtoMäärä
3,5 2 113 939
Välittäjätilasto
Dataa ei löytynyt